ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina: P22
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.07.061
Abstract: Background: Profiling of targetable oncogenic drivers has significantly improved outcomes in patients with nonesmall cell lung cancer (NSCLC). About 40% of individuals with metastatic lung adenocarcinomas may benefit from personalized treatment with kinase inhibitors. There… read more here.
Keywords: patients included; oncogenic drivers; rwt osimertinib; astris rwt ... See more keywords
The long tail of oncogenic drivers in prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "Nature genetics"
DOI: 10.1038/s41588-018-0078-z
Abstract: Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. However, larger and uniform genomic analysis may identify additional recurrently mutated genes… read more here.
Keywords: tail oncogenic; long tail; oncogenic drivers; prostate cancer ... See more keywords
The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.
Sign Up to like & getrecommendations! Published in 2025 at "Future oncology"
DOI: 10.1080/14796694.2025.2475728
Abstract: With the ongoing discovery of various oncogenic driver mutations in metastatic non-small cell lung cancer (mNSCLC), a precision medicine approach has emerged, characterized by targeted therapies for select patient populations. Randomized controlled trials (RCT) remain… read more here.
Keywords: targeted therapies; real world; rare oncogenic; world evidence ... See more keywords
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Sign Up to like & getrecommendations! Published in 2024 at "Biomarker Research"
DOI: 10.1186/s40364-024-00566-0
Abstract: Lung cancer ranks among the most common cancers world-wide and is the first cancer-related cause of death. The classification of lung cancer has evolved tremendously over the past two decades. Today, non-small cell lung cancer… read more here.
Keywords: receptor; cancer; lung cancer; advanced nsclc ... See more keywords
Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.8538
Abstract: 8538 Background: Approximately 5% of NSCLC occurs in patients 50 years or younger (median age:71) representing distinct clinicopathological features. Reports characterizing genomic alterations are scarce. Using a large real-world (RW) dataset, we characterize oncogenic drivers,… read more here.
Keywords: age; drivers immune; young adults; adults non ... See more keywords
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.665484
Abstract: Background Several oncogenic drivers in non-small cell lung cancer (NSCLC) are considered actionable with available or promising targeted therapies. Although targetable drivers rarely overlap with each other, there were a minority of patients harboring co-occurring… read more here.
Keywords: drivers non; actionable oncogenic; oncogenic drivers; occurring potentially ... See more keywords